This is a 2-month study in which eligible ADHD adolescents will be provided with personalized
      VIZO Glasses

A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents

ADHD

This is a pilot, open-label study of a 2-month treatment with VIZO Glasses. Following the
      enrollment, the participants will go through an adjustment process where they will be fitted
      with a personalized pair of VIZO Glasses. The participants will be instructed to wear the
      glasses throughout the day for two months. A follow-up visit at the end of the 2-month
      treatment will be conducted to assess the efficacy of VIZO Glasses on managing ADHD symptoms,
      using the ADHD Rating Scale (ADHD-RS) parent-report questionnaire, the Behavior Rating
      Inventory of Executive Function (BRIEF), the Conners Continuous Performance Test-3, and the
      Clinical Global Impression-Improvement (CGI-I). Safety will be monitored by documentation of
      adverse events.

VIZO Glasses

A Pilot Study to Assess the Efficacy and Safety of a Novel Device (VIZO Glasses) in the Management of ADHD in Adolescents.

The ADHD-RS is a parent report questionnaire that is used to aid in the diagnosis of ADHD in children ranging from ages 5-17. The questionnaire contains 18 symptom items corresponding to the DSM-V criteria for ADHD. The parent rates each symptom item on a 4-point Likert scale ranging from 0 ('Never or Rarely') to 3 ('Very Often'). The total score goes from 0 up to 54. Higher scores mean more symptoms and higher ADHD impairments.

The BRIEF is a standardized measure that captures views of executive functions or self-regulation in the everyday environment. The BRIEF is composed of 86 items, where each item is rated by the parent, using a 3-point Likert scale ranging from 1 ('Never') to 3 ('Often').

Conners' Continuous Performance Test-3 (CPT-3) is an objective test of attention and impulsivity that has been validated in individuals aged 8 years and older.

Based on an interview with the participant, the clinician rates the total improvement on a 7 point scale as follows: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment.

A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status